Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 12/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 3/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | BTK | Q06187 | 9/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 3/20 | 0.36 |
| ▸ | JAK1 | P23458 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2582400 | 0.92 | JAK3 (0.43) | JAK3TBK1IKBKEBTKJAK2 | |
| SCHEMBL12174897 | 0.87 | JAK2 (0.48) | JAK3BTKJAK2JAK1ABL1 | |
| SCHEMBL12174929 | 0.83 | JAK3 (0.40) | JAK3JAK2JAK1ABL1KDR | |
| SCHEMBL12174884 | 0.82 | JAK3 (0.44) | JAK3BTKJAK2JAK1AURKB | |
| SCHEMBL14958115 | 0.81 | JAK3 (0.43) | JAK3BTKJAK2JAK1AURKB | |
| SCHEMBL12174891 | 0.79 | JAK2 (0.49) | JAK3JAK2JAK1ABL1KDR | |
| SCHEMBL2589717 | 0.79 | JAK3 (0.46) | JAK3TBK1BTKJAK2JAK1 | |
| SCHEMBL14957925 | 0.79 | JAK3 (0.46) | JAK3BTKJAK2JAK1HDAC6 | |
| SCHEMBL12174898 | 0.76 | JAK3 (0.41) | JAK3JAK2JAK1ABL1KDR | |
| SCHEMBL14958225 | 0.74 | JAK3 (0.41) | JAK3JAK2JAK1ABL1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | claimed |
| EP-2566867-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | Cellzome Limited (GB) | 2013-03-13 | — | — | EP | claimed |
| WO-2011134831-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2011-11-03 | — | — | WO | claimed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131043-A1 | PYRAZOLE COMPOUNDS AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885TBK1 331/4885IKBKE 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.